Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intensive glucose lowering has previously been shown to increase mortality among persons with advanced type 2 diabetes and a high risk of cardiovascular disease. This report describes the 5-year outcomes of a mean of 3.7 years of intensive glucose lowering on mortality and key cardiovascular events. METHODS: We randomly assigned participants with type 2 diabetes and cardiovascular disease or additional cardiovascular risk factors to receive intensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level of 7 to 7.9%). After termination of the intensive therapy, due to higher mortality in the intensive-therapy group, the target glycated hemoglobin level was 7 to 7.9% for all participants, who were followed until the planned end of the trial. RESULTS: Before the intensive therapy was terminated, the intensive-therapy group did not differ significantly from the standard-therapy group in the rate of the primary outcome (a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) (P=0.13) but had more deaths from any cause (primarily cardiovascular) (hazard ratio, 1.21; 95% confidence interval [CI], 1.02 to 1.44) and fewer nonfatal myocardial infarctions (hazard ratio, 0.79; 95% CI, 0.66 to 0.95). These trends persisted during the entire follow-up period (hazard ratio for death, 1.19; 95% CI, 1.03 to 1.38; and hazard ratio for nonfatal myocardial infarction, 0.82; 95% CI, 0.70 to 0.96). After the intensive intervention was terminated, the median glycated hemoglobin level in the intensive-therapy group rose from 6.4% to 7.2%, and the use of glucose-lowering medications and rates of severe hypoglycemia and other adverse events were similar in the two groups. CONCLUSIONS: As compared with standard therapy, the use of intensive therapy for 3.7 years to target a glycated hemoglobin level below 6% reduced 5-year nonfatal myocardial infarctions but increased 5-year mortality. Such a strategy cannot be recommended for high-risk patients with advanced type 2 diabetes. (Funded by the National Heart, Lung and Blood Institute; ClinicalTrials.gov number, NCT00000620.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those levels predict the risk of cardiovascular disease.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Diabetic kidney disease might also play a role in the arrhythmia-associated mechanism of sudden death in this setting.655”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [655]
Experimental — accuracy not yet measuredIn the citing paper
“However, the belief that HbA1c was a surrogate marker was contradicted by findings from the ACCORD trial that diabetics randomly assigned to intensive treatment that reduced HbA1c levels in fact increased the risk of CVD events [14].”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“For example, intensive hypoglycemic treatments, such as oral hypoglycemics and insulin, substantially reduce fasting glucose and HbA1c levels.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“Similar U-shaped curves were found in a 7-year observational study of persons with T1D and a 22-year observational study of >20,000 persons with T2D.83,84”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citationEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Self-citationGlycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Huxley, R., Barzi, F., & Woodward, M. (2006) · BMJ · doi:10.1136/bmj.38678.389583.7c · Cited by 1,534
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Miller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., et al. (2010) · BMJ · doi:10.1136/bmj.b5444 · Cited by 429
Cited by
Items 601–700 of 1,000
Sun, S., Wang, Y., Pang, S., & Wu, X. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-023-01992-z · Cited by 9
“Additionally, high glycated hemoglobin (HbA1c) is also related to poor outcomes in patients with diabetes and CVD [9].”
BackgroundAcute and chronic complications of diabetes
Grotzke, M. P., & Jones, R. E. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-4975-1.00011-5 · Cited by 9
Use of a very low carbohydrate diet for prediabetes and type 2 diabetes: An audit
Glandt, M., Ailon, N. Y., Berger, S., & Unwin, D. (2024) · Journal of Metabolic Health · doi:10.4102/jmh.v7i1.87 · Cited by 8
“25,26,27 On the other hand, when medications lower glucose, while lowering insulin resistance, such as GLP-1 agonists or SGLT-2 inhibitors, then studies show a reduction in CV events and even mortality.”
BackgroundMargallo, L. M. A., Silveira, N. E., Dantas, J. R., Araújo, P. B., de Oliveira, M. M., Milech, A., Zajdenverg, L., Rodacki, M., & de Oliveira, J. E. (2011) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-3-22 · Cited by 8
Cardiovascular Effects of Noninsulin, Glucose-Lowering Agents: Need for More Outcomes Data
Joshi, P. H., Kalyani, R. R., Blumenthal, R. S., & Donner, T. W. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.030 · Cited by 8
Correlates of low hemoglobin A1c in maintenance hemodialysis patients
Kim, Y., Park, J. C., Molnar, M. Z., Shah, A. P., Benner, D., Kovesdy, C. P., Kopple, J. D., & Kalantar‐Zadeh, K. (2012) · International Urology and Nephrology · doi:10.1007/s11255-012-0208-y · Cited by 8
“Increased mortality in patients with HbA1c \6 % might be related to treatment intensity [29].”
Valensi, P. E., Shában, J., Benroubi, M., Kawamori, R., Borzì, V., Shah, S. N., Wenying, Y., Prusty, V., Hansen, J. B., Gumprecht, J., et al. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.786692 · Cited by 8
Dicarbonyl Stress and Atherosclerosis: Is It All RAGE?
Muniyappa, R., & Srinivas, P. R. (2014) · Diabetes · doi:10.2337/db14-0953 · Cited by 9
“Although difficult to achieve, near-normal glycemic control is not typically associated with further reduction in macrovascular events in patients with type 2 diabetes (4).”
BackgroundIncreased rates of myocardial infarction and deaths in men after sexual activity
Niederseer, D., M�ller, J., & Niebauer, J. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.01.036 · Cited by 8
Joly, D. A., Choukroun, G. J., Combe, C., Dussol, B., Fauvel, J., Halimi, J., Quéré, S., & Fiquet, B. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.01.029 · Cited by 8
“Among them, increasing attention is being given to hypoglycemia [3,4].”
BackgroundWong, C., Lee, J. S., Tam, K., Hung, H., So, W., Shum, C., Lam, C., Cheng, J., Man, S., & Auyeung, T. (2017) · Hong Kong Medical Journal · doi:10.12809/hkmj166140 · Cited by 11
SGLT2 inhibitors and the changing landscape for treatment of diabetes
Liu, S., Lam, A. P., Wazir, A., & Cheema, A. N. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s207515 · Cited by 8
“While strict glycemic control has been shown to reduce the risk of diabetic microvascular complications, its role in preventing cardiovascular disease (CVD) has been less clear.(4,5) Indeed, antihyperglycemic therapies have historically been neutral for cardiovascular (CV) benefit, and all new anti-hyperglycemic agent…”
BackgroundOlmesartan, Microalbuminuria, and Type 2 Diabetes
Lammert, A., Krämer, B. K., & Krüger, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1104826 · Cited by 8
Wang, Y., Wu, H., Yang, J., Ma, J., Li, H., He, X., Xiao, Y., & Pan, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1486655 · Cited by 7
Elbehiry, A., Marzouk, E., Alhumaydhi, F. A., & Abalkhail, A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15051788 · Cited by 9
“In contrast, the Action to Control Cardiovascular Risk in Diabetes trial was stopped early because of increased mortality in the intensive treatment group [166,167].”
Trained immunity: A link between risk factors and cardiovascular disease
Chen, M., Kang, X., Zhang, Y., & Liu, Y. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16472 · Cited by 8
“Persistent cardiovascular risk remains even after glucose-lowering interventions (Gerstein et al., 2011; Nathan et al., 1993; Nathan et al., 2005 Chen et al., 2016; Miao et al., 2004; Miao et al., 2007).”
Li, Q., Deshan, Y., Zeng, G., Jiang, L., Xu, L., Xu, J., Liu, R., Song, Y., Zhao, X., Hui, R., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111751 · Cited by 7
Ross, S. A., Dzida, G. J., Ji, Q., Kaiser, M., Ligthelm, R. J., Meneghini, L., Nazeri, A., Orozco‐Beltrán, D., Pan, C., Svendsen, A. L., et al. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12091 · Cited by 7
“The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial showed a paradoxical increase in all-cause mortality in more intensively treated patients.(9) Although the incidence of severe hypoglycemia was higher in this group, the post hoc analyses did not show a clear correlation between these episodes of hyp…”
BackgroundReevaluating Goals of Insulin Therapy: Perspectives from Large Clinical Trials
Riddle, M. C., & Yuen, K. C. J. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.003 · Cited by 7
Hansen, M., Sonne, D. P., Mikkelsen, S. U., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001803 · Cited by 9
Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku
Suplement, K. P. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0177 · Cited by 18
Tanaka, S., Kanazawa, I., & Sugimoto, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209503 · Cited by 8
Quantifying the Risk Continuum for Cardiovascular Death in Adults with Type 2 Diabetes
Williams, B. A., Blankenship, J. C., Voyce, S. J., Cordova, J. M., Gandhi, P., & Shetty, S. S. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.01.009 · Cited by 8
Type 2 Diabetes: Etiology, Epidemiology, Pathogenesis, Treatment
Burns, C., & Sirisena, I. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_34 · Cited by 9
Zhu, Z., Peng, Z., & Xing, Z. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.883383 · Cited by 7
“Intensified glucose control may lead to a higher incidence of hypoglycemia and higher MACEs (11).”
BackgroundMethodInfluentialCahill, L. E., Warren, R. A., Carew, A. S., Levy, A. P., Ginsberg, H. N., Sapp, J. L., Lache, O., & Rimm, E. B. (2023) · Diabetes Care · doi:10.2337/dc23-0760 · Cited by 8
Bolliger, D., Seeberger, M. D., Buse, G. L., Christen, P., Seeberger, E. E., Ruppen, W., & Filipovic, M. (2011) · Anaesthesia · doi:10.1111/j.1365-2044.2011.06963.x · Cited by 8
“However, more recent, large studies and a meta-analysis have shown that tight glycaemic control is not beneficial and may be deleterious [29–34].”
ResultInfluentialChoosing drugs for the treatment of diabetic neuropathy
Alabdali, M. M., Qrimli, M., Barnett, C., Abraham, A., Breiner, A., Katzberg, H. D., Aljaafari, D., Albulaihe, H. M., Perkins, B. A., & Bril, V. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1067680 · Cited by 7
“The effects on DSP are balanced against the risks of intensive glucose control in type 2 patients as suggested by the Action to Control Cardiovascular Risk in Diabetes study [35].”
BackgroundPreumont, V., Hermans, M. P., Bergman, M., & Buysschaert, M. (2012) · PubMed · doi:10.2143/acb.67.6.2062705 · Cited by 7
Critical Limb Ischemia: Advanced Medical Therapy
Davies, M. G. (2012) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-8-4-3 · Cited by 7
Significance of LDL-C lowering therapy in diabetic patients
Martinez-Hervas, M. S., Carmena, M. R., & Ascaso, M. J. F. (2011) · Clinical Lipidology · doi:10.2217/clp.11.28 · Cited by 7
Saremi, A., Schwenke, D. C., Bahn, G., Ge, L., Emanuele, N., & Reaven, P. D. (2014) · Metabolism · doi:10.1016/j.metabol.2014.10.010 · Cited by 7
“[6] Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff Jr DC, et al.”
BackgroundResultHealth care delivery in type 2 diabetes. A survey in an Italian primary care practice
Modesti, A., Bartaloni, R., Bellagamba, F., Caglieri, R., Cenori, K., Ciampalini, G., Costagli, A., Galloni, V., Papa, C. D., Modesti, L., et al. (2014) · Primary care diabetes · doi:10.1016/j.pcd.2014.04.008 · Cited by 7
Packer, M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13207 · Cited by 9
Glycemic Control in Nonpregnant Adults With Type 2 Diabetes
Tung, E. L., Davis, A. M., & Laiteerapong, N. (2018) · JAMA · doi:10.1001/jama.2018.6798 · Cited by 7
Kobalava, Z. D., & Kiyakbaev, G. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-8-79-91 · Cited by 7
Diabetes and Long-Term Complications
Cagliero, E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00051-2 · Cited by 11
Clinical Update on Nursing Home Medicine: 2011
Messinger‐Rapport, B. J., Morley, J. E., Thomas, D. R., & Gammack, J. K. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.08.007 · Cited by 7
Fernando, M. E., Crowther, R. G., Lazzarini, P. A., Sangla, K. S., Wearing, S. C., Buttner, P. G., & Golledge, J. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819853555 · Cited by 7
Nyström, T., James, S. K., Lindahl, B., Östlund, O., Erlinge, D., Herlitz, J. D., Ömerovic, E., Mellbin, L., Alfredsson, J., Fröbert, O., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0590 · Cited by 7
Uniyal, A., & Narang, M. (2021) · Indian Journal of Medical Specialities · doi:10.4103/injms.injms_17_21 · Cited by 7
Azañedo, D., Bendezú-Quispe, G., Lazo-Porras, M., Cárdenas-Montero, D., Ale, G. J. B., Thomas, N. J., Ceballos, R., & Málaga, G. (2017) · ACTA MEDICA PERUANA · doi:10.35663/amp.2017.342.318 · Cited by 8
Awdishu, L., Moore, T., Morrison, M., Turner, C., & Trzebinska, D. (2019) · Pharmacy · doi:10.3390/pharmacy7030083 · Cited by 9
BAJAJ, H. S., Brown, R. E., Jiandani, D., Venn, K., Al‐Asaad, H., Khandwala, H. M., Steen, O., Abdel‐Salam, S., & Aronson, R. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14084 · Cited by 7
“However, the clinical significance of this modest glucose reduction by itself, and its effect on macrovascular complications, is debatable.(28,29) Overall, because of the dual glycaemic and LDL-c reduction benefit observed in this trial”
BackgroundGoldman, M. P., Corriere, M. A., Craven, T. E., Davis, R. P., Sheehan, M. K., Hurie, J., Velazquez, G., Williams, T. K., Chang, K., & Edwards, M. S. (2020) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2020.10.022 · Cited by 7
Avramoglu, R. K., Laplante, M., Quang, K. L., Deshaies, Y., Després, J., Larose, É., Mathieu, P., Poirier, P., Përusse, L., Vohl, M., et al. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.08.262 · Cited by 8
“Several prominent studies such as ACCORD (10,74) and ADVANCE (75) have shown that aggressive glucose lowering therapy does not always lead to reduced cardiovascular mortality, with data suggesting that reduction of hyperglycemia to near normal levels for up to 5 years does not reduce the risk of atherosclerotic macrov…”
BackgroundMethodInfluentialThe dangers of dogma in medicine
Bellomo, R. (2011) · The Medical Journal of Australia · doi:10.5694/mja11.10866 · Cited by 7
Dangers of Hypoglycemia in Cardiac Patients With Diabetes
DEEDWANIA, P. C. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.2138 · Cited by 7
Liu, M., Pei, J.-Y., Zeng, C. C., Xing, Y., Zhang, Y.-F., Tang, P.-Q., Deng, S., & Hu, X. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i3.101488 · Cited by 7
Pickering, A. N., Richardson, S., Rogal, S. S., Thorpe, C. T., Brach, J. S., & Radomski, T. R. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19550 · Cited by 6
Wang, A., Jiang, R., Su, Z., Zhang, J., Zhao, X., Wu, S., & Guo, X. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006178 · Cited by 6
ACCORD: 5-year outcomes of intensive glycemic control
Wilson, C. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.67 · Cited by 6
Lan, Y.-L., Huang, S.-P., Heng, X.-P., Chen, L., Li, P., Wu, J., Yang, L., Pan, X., Lin, T., Cheng, X.-L., et al. (2014) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-014-1826-2 · Cited by 6
“• 193 • Chin J Integr Med 2015 Mar;21(3):188-195”
BackgroundInfluentialComparative Effectiveness and the Future of Clinical Research in Diabetes
Greenfield, S. (2013) · Diabetes Care · doi:10.2337/dc13-1221 · Cited by 6
The future of inpatient diabetes management: glucose as the sixth vital sign
Rendell, M., Saiprasad, S., Trepp-Carrasco, A. G., & Drincic, A. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.13.1 · Cited by 6
Shlomai, G., Kopel, E., Goldenberg, I., & Grossman, E. (2013) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2013.08.004 · Cited by 6
HbA1c targets for type 2 diabetes: How many, …how far!
Giugliano, D., Ceriello, A., & Esposito, K. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.09.007 · Cited by 6
Mosenzon, O., & Raz, I. (2012) · European Heart Journal Supplements · doi:10.1093/eurheartj/sus003 · Cited by 6
Dipeptidyl Peptidase IV Inhibitors and Ischemic Myocardial Injury
Yoon, A. H., Ye, Y., & Birnbaum, Y. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414524482 · Cited by 6
Korytkowski, M. T., Karslioglu French, E., Brooks, M., DeAlmeida, D., Kanter, J., Lombardero, M., Magaji, V., Orchard, T., & Siminerio, L. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000206 · Cited by 6
“The results of this study are consistent with prior studies demonstrating a high prevalence and incidence of CVD in a patient population with T2D (table 2, figure 1).(7) 28 29 As anticipated, the incidence of CVD was higher among patients with baseline evidence of CVD, which was attributed predominantly to ‘other CVD’…”
ResultChen, J., Chang, C., Kuo, M., Tung, S., Tsao, C., & Tsai, C.-J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.07.009 · Cited by 6
“Moderate degree of weight loss is expected with greater improvement in HbA1c and beneficial effects on biomarkers of cardiovascular risk [34,35].”
BackgroundAre Diabetes Care Providers Too Glucocentric?
Lau, D. C. W. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.10.004 · Cited by 6
Strain, W. D., Paldánius, P. M., & Novartis Pharma AG, B. (2017) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2017.13.02.62 · Cited by 7
“This came juxtaposed with the ACCORD (NCT00000620) study demonstrating a lack of benefit and possible increase in CV risk from intensive glycaemic control in patients with long-term sustained hyperglycaemia.(19) ADVANCE (NCT00949286)(20) and VADT (NCT00032487)(21) did not show a corresponding increase in cardiac death…”
MethodPractice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes
Guthrie, R. M. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1430446 · Cited by 6
Hasslacher, C., Kulozik, F., Platten, I., & Bermejo, J. L. (2014) · journal of Diabetes Research and Clinical Metabolism · doi:10.7243/2050-0866-3-9 · Cited by 8
Linagliptin for the treatment of Type 2 diabetes
Tella, S. H., Aktürk, H. K., & Rendell, M. (2013) · Diabetes Management · doi:10.2217/dmt.13.55 · Cited by 6
Yami, M. S. A., Alfayez, O. M., & Alsheikh, R. (2018) · Heart Lung and Circulation · doi:10.1016/j.hlc.2018.03.018 · Cited by 6
“In fact, very intensive glycaemic control might be associated with increased CV mortality [3].”
Xiong, R., He, L., Du, X., Dong, J., & Ma, C. (2020) · Clinical Cardiology · doi:10.1002/clc.23373 · Cited by 8
“5 years because there were 22% more mortality in patients who were controlled intensively.(26) Nowadays, several studies which were designed to reduce the MACEs in this high-risk population with glucose lowering agents suggest only specific anti-diabetic drugs decrease MACEs,(27-30) in addition the impact indicates no…”
BackgroundResultGoshima, Y., Okada, Y., Torimoto, K., Fujino, Y., & Tanaka, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-72341-8 · Cited by 8
Intensive Insulin Therapy (Basal-Bolus)
Chico, A. I., & Corcoy, R. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001152 · Cited by 6
Association of UBE3C Variants with Reduced Kidney Function in Patients with Diabetic Kidney Disease
Chen, Y.-C., Wu, M., Yu, Z.-L., Chou, W., Lai, Y.-T., Kao, C., Faridah, I. N., Wu, M.-S., & Chang, W. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040210 · Cited by 6
“However, intensive glucose control to achieve stringent targets could also negatively affect mortality [9,10].”
BackgroundHypoglycemia, its implications in clinical practice, and possible ways to prevent it
Maffioli, P., & Derosa, G. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.890096 · Cited by 6
Zhou, H., Huang, Y., Xie, P., Zhang, S., Liu, M., Xiong, Z., Huang, R., Xu, X., Li, M., Zhou, Z., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.035788 · Cited by 5
“26 In brief, ACCORD enrolled 10 251 people with T2D and previous evidence or high risk of CVD across the United States and Canada from June 2001 through October 2005.”
Immune Dysregulation Connecting Type 2 Diabetes and Cardiovascular Complications
Deck, K. S., Mora, C. J., Deng, S., Rogers, P., Rafferty, T. M., Palade, P., Mu, S., & Liu, Y. (2025) · Life · doi:10.3390/life15081241 · Cited by 10
Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus
Kapoor, K., George, P., & Miller, M. J. (2016) · Cardiology · doi:10.1159/000446471 · Cited by 5
The Management of Diabetic Patients with Heart Failure
Rosano, G. M. C., & Seferovic, P. M. (2017) · International Cardiovascular Forum Journal · doi:10.17987/icfj.v10i0.449 · Cited by 5
“[20] The Eplerenone Post- Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) also found a 38% increased risk of a poorer outcome among patients with hypoglycaemia complicating HF post- MI.”
BackgroundWang, J.-M., Miao, M.-Y., Jia, Y., Wang, X., Wu, X., Wan, Z., Zheng, Y., Qin, L., Li, F., & Chen, G. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111100 · Cited by 7
Glucose‐lowering medicines use before and after entry into long‐term care facilities
Wondimkun, Y. A., Caughey, G. E., Inacio, M. C. S., Air, T., Lang, C. E., & Sluggett, J. K. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15905 · Cited by 5
“34,35 This is concerning for residents of LTCFs because they are often frail and have multimorbidity.”
Ji, K., Han, M., Yang, M., Xu, Q., & Zhang, Y. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1454647 · Cited by 6
Prasad, M., Agrón, E., Vitale, S., Arunachalam, T., Duic, C., Siddig, F., Dimopoulos, I. S., Lu, A. Q., & Chew, E. Y. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.07.018 · Cited by 5
Función plaquetaria e hiperglucemia en el síndrome coronario
Puig‐Domingo, M. (2013) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.08.012 · Cited by 8
Apolipoprotein-defined and NMR lipoprotein subclasses in the Veterans Affairs Diabetes Trial
Azar, M., Lyons, T. J., Alaupovic, P., Stoner, J. A., Quiroga, C., Kaufman, D., Lopes-Virella, M. F., Klein, R. L., & Jenkins, A. J. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.05.005 · Cited by 6
Platelet Function and Hyperglycemia in Acute Coronary Syndrome
Puig‐Domingo, M. (2013) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.08.011 · Cited by 5
Pre-participation Examination of Competitive Athletes: Role of the ECG
Hirzinger, C., Froelicher, V. F., & Niebauer, J. (2010) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2011.06.001 · Cited by 7
Li, W., Min, R., Dong, Y., Li, Z., Sun, Q., & Li, Y. (2013) · journal of Diabetes Research and Clinical Metabolism · doi:10.7243/2050-0866-2-15 · Cited by 5
“Therefore, we conducted an open-label, randomized cross-over study in T2DM patients to investigate glucose variation of switching Li et al. Journal of Diabetes Research & Clinical Metabolism 2013, http://www.hoajonline.com/journals/pdf/2050-0866-2-15.pdf doi: 10.7243/2050-0866-2-15 from PHI 70/30 to LM25 or LM50 with…”
BackgroundInfluentialTop 20 research studies of 2011 for primary care physicians.
Ebell, M. H., & Grad, R. M. (2012) · PubMed · Cited by 5
Cardioprotective Effects of Pioglitazone in Type 2 Diabetes
Tripathy, D., Solis‐Herrera, C., & Ryder, R. E. J. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0078 · Cited by 7
“However, the effect of glycemic control on macrovascular disease, particularly cardiovascular disease (CVD), is not clear (5,6).”
BackgroundInzucchi, S. E., & Sherwin, R. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00562-5 · Cited by 6
Kanazawa, I., & Sugimoto, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201055 · Cited by 6
The effect of consumption of inulin‐enriched Turrón upon blood serum lipids over a 5‐week period
García‐García, E., Narbona, E., Carbonell-Barrachina, Á. A., Sánchez-Soriano, J., & Roche, E. (2012) · International Journal of Food Science & Technology · doi:10.1111/j.1365-2621.2012.03202.x · Cited by 5
Cordiano, R. (2013) · International Journal of Cardiovascular Research · doi:10.4172/2324-8602.1000160 · Cited by 5
“Indeed, the present study suggests that in ACS patients, therapeutic efforts should be aimed at both lowering and maintaining glycemic levels in a range approximating central quartiles [21].”
BackgroundPrise en charge du diabète de type 2 : anciens ou nouveaux médicaments, comment choisir ?
Halimi, S. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.04.002 · Cited by 6
“[7] Gerstein HC, Miller ME, Genuth S, IsmailBeigi F, Buse JB, Goff DCJr.”
Wing, J., & Jivan, D. (2015) · South African Medical Journal · doi:10.7196/samj.2016.v106i1.10284 · Cited by 6
Obesity Surgery and the Risk of Colorectal Carcinoma—Searching for the Fly in the Ointment?
Raptis, D. A., Bächler, T., Nocito, A., & Bueter, M. (2013) · Annals of Surgery · doi:10.1097/sla.0000000000000464 · Cited by 5
Koh, K. K. (2018) · Circulation · doi:10.1161/circulationaha.117.030650 · Cited by 5
Debate: Testosterone Therapy Reduces Cardiovascular Risk in Men with Diabetes. Against the Motion
Schooling, C. M., Xu, L., & Zhao, J. V. (2015) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-015-0449-2 · Cited by 4
Efectos cardiovasculares y seguridad de los fármacos hipoglucemiantes: situación actual
Masmiquel, L. (2013) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2012.12.001 · Cited by 7
“Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.”
Ensuring Patient Safety During the Transition to ESRD
Wagner, L.-A., & Fink, J. C. (2017) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.12.009 · Cited by 4
Siedlecki, Ł., Szyguła‐Jurkiewicz, B., Pyka, Ł., Król, B., Szczurek, W., & Gąsior, M. (2017) · Polish Journal of Cardio-Thoracic Surgery · doi:10.5114/kitp.2017.70530 · Cited by 4
Kloecker, D. E., Davies, M. J., Pitocco, D., Khunti, K., & Zaccardi, F. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3634 · Cited by 4
“ACCORDION study; the details and main results of these two studies have been reported previously.(3,10,26,27) In ACCORD, 10,251 participants with type 2 diabetes and previous evidence, or at high risk, of cardiovascular disease were randomised to intensive (HbA1c target of <6% [42 mmol/mol]) or standard [7%–7.”
Result
Metadata
- Authors
- The ACCORD Study Group
- Affiliations
- McMaster University (CA)
- Corresponding author
- The ACCORD Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-03-03
- Volume
- 364
- Issue
- 9
- Pages
- 818-828
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4083508
- OpenAlex
- W2125468958
- Cited by
- 1,035
- References
- 18
- Citations by year
- 2026: 12 · 2025: 33 · 2024: 27 · 2023: 35 · 2022: 29 · 2021: 61 · 2020: 51 · 2019: 53 · 2018: 81 · 2017: 78 · 2016: 80 · 2015: 91 · 2014: 100 · 2013: 108 · 2012: 120
- FWCI
- 104.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, Y1-HC-9035, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, N01 HC095180, Y01 HC009035, Y1-HC-1010, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, HbA1c, cardiovascular outcomes, mortality, myocardial infarction, stroke, cardiovascular disease, glycemic targets, hypoglycemia, adverse events, long-term follow-up, EXSCEL trial
- MeSH terms
- Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Proportional Hazards Models, Treatment Outcome, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.